A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

被引:265
作者
Yin, JJ
Mohammad, KS
Käkönen, SM
Harris, S
Wu-Wong, JR
Wessale, JL
Padley, RJ
Garrett, IR
Chirgwin, JM
Guise, TA
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Drug Dev, San Antonio, TX 78245 USA
[2] Univ Missouri, Dept Oral Biol, Kansas City, MO 64108 USA
[3] Abbott Labs, Santa Clara, CA 95054 USA
[4] Abbott Labs, Dept R46R, Abbott Pk, IL 60064 USA
[5] Abbott Labs, Dept 42R, Abbott Pk, IL 60064 USA
[6] Osteoscreen Inc, San Antonio, TX 78229 USA
关键词
D O I
10.1073/pnas.1830978100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Osteoblastic bone metastases are common in prostate and breast cancer patients, but mechanisms by which tumor cells stimulate new bone formation are unclear. We identified three breast cancer cell lines that cause osteoblastic metastases in a mouse model and secrete endothelin-1. Tumor-produced endothelin-1 stimulates new bone formation in vitro and osteoblastic metastases in vivo via the endothelin A receptor. Treatment with an orally active endothelin A receptor antagonist dramatically decreased bone metastases and tumor burden in mice inoculated with ZR-75-1 cells. Tumor-produced endothelin-1 may have a major role in the establishment of osteoblastic bone metastases, and endothelin A receptor blockade represents effective treatment.
引用
收藏
页码:10954 / 10959
页数:6
相关论文
共 43 条
[1]   AN ASSAY FOR TRANSFORMING GROWTH-FACTOR-BETA USING CELLS TRANSFECTED WITH A PLASMINOGEN-ACTIVATOR INHIBITOR-1 PROMOTER LUCIFERASE CONSTRUCT [J].
ABE, M ;
HARPEL, JG ;
METZ, CN ;
NUNES, I ;
LOSKUTOFF, DJ ;
RIFKIN, DB .
ANALYTICAL BIOCHEMISTRY, 1994, 216 (02) :276-284
[2]  
ACHBAROU A, 1994, CANCER RES, V54, P2372
[3]   ENDOTHELIN INHIBITS OSTEOCLASTIC BONE-RESORPTION BY A DIRECT EFFECT ON CELL MOTILITY - IMPLICATIONS FOR THE VASCULAR CONTROL OF BONE-RESORPTION [J].
ALAM, ASMT ;
GALLAGHER, A ;
SHANKAR, V ;
GHATEI, MA ;
DATTA, HK ;
HUANG, CLH ;
MOONGA, BS ;
CHAMBERS, TJ ;
BLOOM, SR ;
ZAIDI, M .
ENDOCRINOLOGY, 1992, 130 (06) :3617-3624
[4]  
[Anonymous], SCI MATH
[5]   Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ETA receptor antagonism [J].
Asham, E ;
Shankar, A ;
Loizidou, M ;
Fredericks, S ;
Miller, K ;
Boulos, PB ;
Burnstock, G ;
Taylor, I .
BRITISH JOURNAL OF CANCER, 2001, 85 (11) :1759-1763
[6]   Determination of atrasentan by high performance liquid chromatography with fluorescence detection in human plasma [J].
Bryan, PD ;
Sapochak, LB ;
Tames, MM ;
Padley, RJ ;
El-Shourbagy, TA .
BIOMEDICAL CHROMATOGRAPHY, 2001, 15 (08) :525-533
[7]   Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics [J].
Carducci, MA ;
Nelson, JB ;
Bowling, MK ;
Rogers, T ;
Eisenberger, MA ;
Sinibaldi, V ;
Donehower, R ;
Leahy, TL ;
Carr, RA ;
Isaacson, JD ;
Janus, TJ ;
Andre, A ;
Hosmane, BS ;
Padley, RJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) :2171-2180
[8]   Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption [J].
Chiao, JW ;
Moonga, BS ;
Yang, YM ;
Kancherla, R ;
Mittelman, A ;
Wu-Wong, JR ;
Ahmed, T .
BRITISH JOURNAL OF CANCER, 2000, 83 (03) :360-365
[9]   Establishment and characterization of osseous prostate cancer models: Intra tibial injection of human prostate cancer cells [J].
Corey, E ;
Quinn, JE ;
Bladou, F ;
Brown, LG ;
Roudier, MP ;
Brown, JM ;
Buhler, KR ;
Vessella, RL .
PROSTATE, 2002, 52 (01) :20-33
[10]  
de Matteis A, 2001, CANCER, V91, P1933, DOI 10.1002/1097-0142(20010515)91:10<1933::AID-CNCR1216>3.0.CO